A major marijuana company has announced that it will begin supplying cannabis to a Spanish clinical trial investigating marijuana’s potential as a glioblastoma treatment. Tilray Brands subsidiary Tilray Medical will sponsor an upcoming clinical study to test whether marijuana can treat glioblastoma, one of the hardest-to-treat types of brain cancer.
The study will be conducted by Complutense University of Madrid and Spanish Neuro-Oncology Research Group (GEINO) scientists at Madrid’s University Hospital. For the research, researchers will recruit 30 recently diagnosed glioblastoma patients from eight neurooncology specialized sites in Spain, they will use T10:C10, a THC and CBD extract from Tilray Medical alongside radiation therapy and oral drug temozolomide to treat the cancer.
It is likely the first-ever study to investigate whether marijuana can alleviate glioblastoma, a type of cancer that doesn’t respond to most treatments and has very low survival outcomes.
According to Tilray Medical’s chief strategy officer Denise Faltischek, the “groundbreaking trial” presents Tilray with a chance to take part in cutting-edge medical research and could open new treatment avenues for glioblastoma patients. GEINO neurologist Dr. Juan Manuel will lead the study, with funding from Amsterdam-based charity Medical Cannabis Bike Tour Foundation (MCBTF).
The clinical trial comes after a decade of collaboration between the medical marijuana community and the scientific sector, Tilray says. MCBTF started raising funds for the research project more than 10 years ago to support Complutense University of Madrid scientists who were researching the potential of cannabinoids in cancer treatment at the time.
Over the past 20 years or so, extensive medical cannabis research has revealed that cannabis has plenty of medical potential and can aid in the treatment of conditions such as inflammatory bowel disease (IBD), Crohn’s disease and post-traumatic stress disorder. Cannabinoids can also help cancer patients deal with symptoms such as insomnia and lack of appetite and have also shown that they can slow down cancer cell growth or even kill some types of cancer cells.
With biological evidence of marijuana’s therapeutic potential accumulating for more than 15 years, especially regarding cannabinoids’ ability to suppress tumor activity, cannabis may be able to alleviate glioblastoma symptoms as well. The upcoming Spanish trial will finally allow researchers to study how cannabinoids affect glioblastomas that haven’t received active treatment.
MCBTF founder Luc Krol says that after a decade of fundraising, it is “amazing” that the charity can fund a clinical trial independently.
If the trial finds that cannabis does have some potential as a glioblastoma treatment, it could open up the door to novel treatments for an incredibly hard-to-treat condition. This avenue adds to other options for glioblastoma being explored by drug development companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP).
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN